{ "schemaVersion": "deck-intelligence.v1", "id": "019de072-afcf-751b-be79-65bbe03fb0c7", "slug": "a4681640730b4446aa1f6ee077b8a572", "title": "Compass Therapeutics | Investor Presentation Deck | 23 slides", "subtitle": "Compass Therapeutics · 2022-05", "author": "Compass Therapeutics", "date": "2022-05-01 00:00:00", "pageCount": 23, "kind": "pitchdeck", "orientation": "landscape", "aspectRatio": 1.7777778, "document": { "id": "019de072-afcf-751b-be79-65bbe03fb0c7", "slug": "a4681640730b4446aa1f6ee077b8a572", "title": "Compass Therapeutics | Investor Presentation Deck | 23 slides", "rawTitle": "Compass Therapeutics | Investor Presentation Deck | 23 slides", "authorId": "compass-therapeutics", "authorName": "Compass Therapeutics", "authorDisplay": "Compass Therapeutics", "kind": { "slug": "pitchdeck", "label": "Pitch deck" }, "sourceType": { "slug": "investor_relations", "label": "Investor relations" }, "fileName": "2022-05__compass-therapeutics__investor-pres__a4681640.pdf", "sourceUrl": "https://www.slidebook.io/company/compass-therapeutics/presentation/a4681640730b4446aa1f6ee077b8a572/", "sourceDate": "2022-05-15 00:00:00", "presentationDate": "2022-05-01 00:00:00", "ingestedAt": "2026-04-30 22:11:45.846936+00", "status": "ready", "pageCount": 23, "orientation": "landscape", "aspectRatio": 1.7777778, "targetCompany": null, "targetTicker": null, "metadata": { "corpus": "slidebook", "industry": "biotechnology", "local_root": "/Users/miguelsuredasuau/Desktop/lalalalla/_scrape/slidebook/decks/2022-05__compass-therapeutics__investor-pres__a4681640", "image_width": 1920, "image_format": "jpg", "deck_type_raw": "Investor Presentation Deck", "deck_type_slug": null, "source_url_pattern": "https://www.slidebook.io/company/{company_slug}/presentation/{deck_id}/" } }, "coverage": { "pageCount": 23, "pagesIndexed": 23, "pagesWithImages": 23, "pagesWithMetadata": 23, "imageCoveragePct": 100, "metadataCoveragePct": 100, "componentCount": 100, "chartCount": 4, "metricSlides": 0, "toolMatches": 10, "documentToolMatches": 0, "frameworkMatches": 5, "arcMatches": 1, "beatMatches": 4, "loopMatches": 1, "patternMatches": 0, "storymakersMatch": false, "scoreAvailable": false, "reviewAvailable": false, "activistThesisAvailable": false, "pitchdeckMetadataAvailable": false, "pitchdeckProfileAvailable": false }, "blocks": [], "matches": { "arcs": [ { "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "matchId": "f3296a8e-e181-40c4-ac34-35cba57d4f6c", "evidence": "The deck follows a structure similar to the Sequoia Pitch, with sections on problem, solution, market size, product, and team", "isPrimary": true, "confidence": 0.8, "extraction": { "at": "2026-07-16 22:21:57.713016+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "beats": [ { "to": 3, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 3, "name": "Problem", "beatId": "706587f7-3254-4856-9a3c-57a4f888e4b3", "matchId": "f3296a8e-e181-40c4-ac34-35cba57d4f6c", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "The executive summary presents the company's focus on cancer and autoimmune diseases", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 7, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 7, "name": "Solution", "beatId": "88e44242-ad4a-482c-b72f-501a68ee73eb", "matchId": "f3296a8e-e181-40c4-ac34-35cba57d4f6c", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The vision and potential section presents CTX-009 as a potential solution", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 12, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 8, "name": "Product", "beatId": "c48aac4e-cbcc-46b6-a057-f734bc543a6f", "matchId": "f3296a8e-e181-40c4-ac34-35cba57d4f6c", "beatType": { "name": "Product", "slug": "sequoia-pitch-product", "status": "active", "canonId": "019dd9b8-2259-77df-a937-8b665c8066fe", "version": 1, "description": null }, "evidence": "The traction section presents clinical data for CTX-009", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 4, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 4, "name": "Team", "beatId": "71a3ea24-1623-4157-b008-1b14b37e7bbc", "matchId": "f3296a8e-e181-40c4-ac34-35cba57d4f6c", "beatType": { "name": "Team", "slug": "sequoia-pitch-team", "status": "active", "canonId": "019dd9b8-23c9-746f-aaf9-2f5d83892cf3", "version": 1, "description": null }, "evidence": "The team bio section presents the company's leadership team", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 23, "from": 3, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null, "categoryName": "Urgency", "categorySlug": "urgency" }, "matchId": "623768d0-5f70-4f8f-9e81-1e86d7a34667", "evidence": "The deck presents a sense of urgency and potential benefits of investing in the company", "position": 0, "objective": "Highlight the potential consequences of not investing in Compass Therapeutics", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:21:57.918341+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "0e090a8f-9fc2-47de-9fc7-00af57cdebbd", "evidence": "title/headline: Compass Therapeutics Presentation May 2022", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:00:30.989711+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "6b226ab5-3adf-4ed5-a637-5a8d5e3e58d3", "evidence": "list/bullet: We are a clinical stage biotech company", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:00:31.249331+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Gantt chart", "slug": "gantt-chart", "status": "active", "bestFor": null, "canonId": "019de52d-1fa2-7206-bb14-bb9ff5fccdba", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "17f8af27-8194-424b-ae14-78fe296eaf53", "evidence": "framework/instance: Gantt-style clinical development timeline", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:00:31.441164+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Section divider", "slug": "section-divider", "status": "active", "bestFor": null, "canonId": "019dd9e1-4c66-707d-8d1f-6e14547134c7", "version": 1, "bodyDocId": null, "description": "A transitional slide marking the start of a new section.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "88341ce8-75e7-45b3-a009-9768d3e6da38", "evidence": "paragraph/paragraph: CTX-009 – DLL4 X VEGF-A bispecific antibody", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:00:31.56609+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "6dfa0ce8-7f12-4627-a26b-f26340958b08", "evidence": "table/data: Right table showing Prior systemic therapies, Prior Gem/Cis regimen, and BTC subtype for 24 patients.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:00:30.744076+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "38ea3ed8-8974-4deb-bd52-0d37bd7060ae", "evidence": "chart/waterfall: Waterfall plot of percent tumor decline by patient", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:00:30.897269+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Sparklines (Chart)", "slug": "sparklines-chart", "status": "active", "bestFor": null, "canonId": "019dd956-b3db-7239-aa95-d24b7cdc29e4", "version": 1, "bodyDocId": null, "description": "Word-sized graphics embedded in text for data density", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "6d9ff104-83e3-4ea2-be94-96f4a94efa2a", "evidence": "chart/bar-horizontal: Swimmer plot showing patient treatment duration", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:00:31.040103+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "f4d3868b-a445-48ed-8cf7-bc0b9730f2be", "evidence": "table/data: Phase 2 BTC study of CTX-009 plus paclitaxel table", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:00:31.147355+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "4eeff147-fa1c-4fa6-a837-389572a81191", "evidence": "list/bullet: 24 patients with BTC have been enrolled and dosed", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:00:31.320725+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 15, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "daeddc9d-50de-42be-ae24-a25cfb82c367", "evidence": "list/bullet: Phase 1 Study Update", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:00:31.439705+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 17, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "0edec7f2-091f-4fba-b4fd-97bb38d9e417", "evidence": "Visual representation of project schedules and milestones over time.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:52:20.516+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "frameworkName": "gantt-chart" }, { "matchId": "e8d09af9-daaa-4808-bf99-2e27a066871a", "evidence": "Explicit mention of 'Simon 2 Stage adaptive design' and stage-gate criteria.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:52:21.638+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "frameworkName": "Simon 2-Stage Design" }, { "matchId": "db6757e7-b212-42e4-b115-4464aafee089", "evidence": "Standard clinical trial efficacy visualization", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:52:21.628+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "frameworkName": "waterfall-chart" }, { "matchId": "d90efd02-f67d-438d-9a6c-9204e517492d", "evidence": "Standard clinical trial visualization for patient-level longitudinal data", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:52:25.88+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "frameworkName": "swimmer-plot" }, { "matchId": "c68532ab-48ec-4b8e-9c20-fc6c12f161d3", "evidence": "Visual representation of milestones over time", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:52:22.248+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 23, "frameworkName": "gantt-chart" } ], "patterns": [] }, "storymakers": null, "score": null, "review": null, "activistThesis": null, "pitchdeck": { "metadata": null, "profile": null }, "slides": [ { "page": 1, "type": "setup", "function": "front_matter", "imagePath": "https://imgproxy.kitesheet.com/uBToImjMzCcWhPX66mZ5QTRSUA1wFGSaIbeZgT3lbs0/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9hNDY4MTY0MDczMGI0NDQ2YWExZjZlZTA3N2I4YTU3Mi9wMDAxLmpwZw", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 24, "componentCount": 4, "textChars": 145, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:52:19.225+00", "seconds": 2.14, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de072-afcf-751b-be79-65bbe03fb0c7/1", "deck": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7", "deckAnchor": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7#slide-1", "deckJson": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7.json" }, "components": [ { "bbox": { "h": 0.03, "w": 0.24, "x": 0.38, "y": 0.94 }, "kind": "disclaimer", "text": "DO NOT DISTRIBUTE WITHOUT PERMISSION | © 2022", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:19.225+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "91af8e31-1eac-4cb4-85f6-38a0ba4ad4a5", "parentComponentId": null }, { "bbox": { "h": 0.8, "w": 1, "x": 0, "y": 0.2 }, "kind": "image", "text": "Molecular structure visualization", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:19.225+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "498acc12-d7bd-4ad5-8b07-4f3f7a696044", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.24, "x": 0.025, "y": 0.05 }, "kind": "image", "text": "Compass Therapeutics logo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:19.225+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d6df7816-19ef-49c9-93ff-4bc2ed2139b5", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.75, "x": 0.23, "y": 0.3 }, "kind": "title", "text": "Compass Therapeutics Presentation May 2022", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:19.225+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e077ffa2-d881-4961-a2aa-253d85d589ec", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "0e090a8f-9fc2-47de-9fc7-00af57cdebbd", "evidence": "title/headline: Compass Therapeutics Presentation May 2022", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:00:30.989711+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "thumbSrc": "https://imgproxy.kitesheet.com/SQPtvKEp26TaLV60fG7Ys8f5kVf4ht2sn59elt-Vgzc/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9hNDY4MTY0MDczMGI0NDQ2YWExZjZlZTA3N2I4YTU3Mi9wMDAxLmpwZw", "imagePathAlt": "https://imgproxy.kitesheet.com/Dc44JfA0Q5DGuSguUP5mZi-uCNLfoYB2xoAH_szmfP0/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9hNDY4MTY0MDczMGI0NDQ2YWExZjZlZTA3N2I4YTU3Mi9wMDAxLnBuZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/LK423Ox-AYiA9pTOtlEAScnhMwyQgu030ILnHkgio3E/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9hNDY4MTY0MDczMGI0NDQ2YWExZjZlZTA3N2I4YTU3Mi9wMDAxLnBuZw" }, { "page": 2, "type": "setup", "function": "other", "rawType": "disclaimer", "block": null, "metadata": { "slideType": "disclaimer", "slideTypeCanon": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "019de52d-0801-727b-b98a-5ed095aeee78", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "dense", "densityScore": 71, "componentCount": 6, "textChars": 3260, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:52:21.882+00", "seconds": 4.578, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de072-afcf-751b-be79-65bbe03fb0c7/2", "deck": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7", "deckAnchor": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7#slide-2", "deckJson": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.9, "x": 0.05, "y": 0.72 }, "kind": "disclaimer", "text": "This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:21.882+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4440e6c9-f65a-4b84-a40a-79386b5d9609", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.9, "x": 0.05, "y": 0.37 }, "kind": "disclaimer", "text": "This presentation includes forward-looking statements regarding our drug candidates, the timing of the start and conclusion of ongoing or planned clinical trials, including the potential impact of the ongoing COVID-19 pandemic on our business, the timing and outcome of regulatory decisions, future availability of clinical trial data, our collaborations for our product candidates and the maintenance of those collaborations, business and results from operations, and other matters. Actual results could differ materially from those contained in any forward-looking statements as a result of various factors, including without limitation: that our drug candidates do not advance in development or result in approved products on a timely or cost effective basis or at all; the cost, timing and results of clinical trials; our ability to manage and mitigate the impact of the ongoing COVID-19 pandemic; that many drug candidates that have completed early-stage trials do not become approved drugs on a timely or cost effective basis or at all; the ability to enroll patients in clinical trials; regulatory developments; our ability to protect our intellectual property rights, and unexpected costs, charges or expenses that reduce cash runway. Our pipeline programs are in various stages of pre-clinical and clinical development, and the process by which such pre-clinical or clinical therapeutic candidates could potentially lead to an approved therapeutic is long and subject to significant risks and uncertainties. These and other risks and uncertainties that we face are described in our most recent Annual Report on Form 10-K, and in other filings that we make with the Securities and Exchange Commission from time to time. We undertake no obligation to update forward-looking statements as a result of new information or otherwise.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:21.882+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "af219b83-352f-477c-bbaa-0e4e0a7355c2", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.9, "x": 0.05, "y": 0.81 }, "kind": "disclaimer", "text": "This presentation concerns drugs that are under clinical investigation, and which have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA). It is currently limited by Federal law to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:21.882+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c60ce66c-0900-49ff-822d-42d6ae883097", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.9, "x": 0.05, "y": 0.25 }, "kind": "disclaimer", "text": "This presentation has been prepared by Compass Therapeutics, Inc. (\"we,\" \"us,\" \"our,\" or the \"Company\"). Statements contained herein are made as of the date of this presentation unless stated otherwise, and this presentation shall not under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:21.882+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d4805361-c0b8-4b0e-8054-10a59eab141c", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.24, "x": 0.38, "y": 0.95 }, "kind": "source-note", "text": "DO NOT DISTRIBUTE WITHOUT PERMISSION | © 2022", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:21.882+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "edbd1904-ed73-4acb-a6ac-3f6740216e8b", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.25, "x": 0.05, "y": 0.14 }, "kind": "title", "text": "DISCLAIMER", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:21.882+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1255d396-5038-40aa-a0de-f1531a526944", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 3, "type": "setup", "function": "establish_context", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "establish_context", "functionCanon": { "name": "Establish context", "slug": "establish_context", "status": "active", "canonId": "019de52d-1314-74e6-9074-d213dc0bdcdf", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 81, "componentCount": 8, "textChars": 701, "nDataPoints": 1, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:52:20.323+00", "seconds": 2.963, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de072-afcf-751b-be79-65bbe03fb0c7/3", "deck": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7", "deckAnchor": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7#slide-3", "deckJson": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.65, "x": 0.02, "y": 0.25 }, "kind": "callout", "text": "CORE SCIENCE", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.323+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "38fd9c7e-654b-4d4b-8572-9d1a242d884e", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.58, "x": 0.02, "y": 0.74 }, "kind": "callout", "text": "RESOURCES", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.323+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6a185329-ba15-4e2b-ba38-5b28ce67f5b7", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.58, "x": 0.4, "y": 0.47 }, "kind": "callout", "text": "FOCUS", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.323+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a20fe408-4163-49e0-8875-68d60e277e28", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.58, "x": 0.4, "y": 0.54 }, "kind": "list", "text": "Next Generation novel antibody therapeutics\nKey programs: CTX-009, CTX-471 and CTX-8371\nLet the science guide the therapeutic format: monoclonal vs. multispecific", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.323+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6c3a2c39-f4ad-46e5-95ec-ea8b7f8ee861", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.7, "x": 0.02, "y": 0.32 }, "kind": "list", "text": "StitchMabs™ platform designed to identify synergistic bispecific antibodies\nCommon Light Chain technology enables multi-specificity and manufacturability\nOur understanding of Cancer Biology informs the design of our proprietary drug candidates", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.323+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "98415b85-65b8-40a2-a3ee-e7a7091f531d", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.6, "x": 0.02, "y": 0.8 }, "kind": "list", "text": "~25 FTEs, based in Boston, MA\nCapable of rapidly advancing candidates from idea to clinical proof-of-concept\nFunded by leading life-science investors", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.323+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c39c2852-e82d-41fb-9ef8-5dde2c05f7bf", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.6, "x": 0.2, "y": 0.12 }, "kind": "paragraph", "text": "We are a clinical stage biotech company developing antibody therapeutics for cancer & autoimmune diseases", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.323+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6032c772-b1cb-40e4-b8b4-0fd19f3fe740", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.3, "x": 0.02, "y": 0.03 }, "kind": "title", "text": "Company Overview", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.323+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "aeecf998-f2b4-4939-9048-f7b8d860a995", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "6b226ab5-3adf-4ed5-a637-5a8d5e3e58d3", "evidence": "list/bullet: We are a clinical stage biotech company", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:00:31.249331+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 3, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 3, "name": "Problem", "beatId": "706587f7-3254-4856-9a3c-57a4f888e4b3", "matchId": "f3296a8e-e181-40c4-ac34-35cba57d4f6c", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "The executive summary presents the company's focus on cancer and autoimmune diseases", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 23, "from": 3, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "623768d0-5f70-4f8f-9e81-1e86d7a34667", "evidence": "The deck presents a sense of urgency and potential benefits of investing in the company", "position": 0, "objective": "Highlight the potential consequences of not investing in Compass Therapeutics", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:21:57.918341+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 4, "type": "setup", "title": "The slide is divided into Senior Executive Team (CEO, COO, CSO, CMC, VPs) and Board of Directors.", "function": "other", "rawType": "team_bio", "block": null, "metadata": { "slideType": "team_bio", "slideTypeCanon": { "name": "Team bio", "slug": "team_bio", "status": "active", "canonId": "019de52d-0a7d-7394-ae5b-037478e71f1e", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "dense", "densityScore": 63, "componentCount": 9, "textChars": 297, "nDataPoints": 0, "notes": "The slide is divided into Senior Executive Team (CEO, COO, CSO, CMC, VPs) and Board of Directors.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:52:26.169+00", "seconds": 8.738, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de072-afcf-751b-be79-65bbe03fb0c7/4", "deck": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7", "deckAnchor": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7#slide-4", "deckJson": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7.json" }, "components": [ { "bbox": { "h": 0.3, "w": 0.15, "x": 0.06, "y": 0.25 }, "kind": "image", "text": "Thomas J. Schuetz, MD, PhD", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:26.169+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3193f364-3010-4201-a49f-f9e1f30d374f", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.15, "x": 0.11, "y": 0.67 }, "kind": "image", "text": "Jon Anderman", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:26.169+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "80138e69-882b-463d-8034-913280912d1e", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.15, "x": 0.27, "y": 0.67 }, "kind": "image", "text": "Bing Gong, PhD", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:26.169+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "848496a2-5254-4450-85d8-ea93dcfcf0a6", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.15, "x": 0.54, "y": 0.25 }, "kind": "image", "text": "Peter Moesta", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:26.169+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "853ff635-55b3-44ce-8f9d-74f71950c359", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.15, "x": 0.43, "y": 0.67 }, "kind": "image", "text": "Neil Lerner, CPA, MIM", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:26.169+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a8fd3e26-7e19-4330-a5de-4d7cd6912970", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.15, "x": 0.22, "y": 0.25 }, "kind": "image", "text": "Vered Bisker-Leib, PhD, MBA", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:26.169+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c1df452e-7337-4d67-8a29-e55318fe46ef", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.15, "x": 0.38, "y": 0.25 }, "kind": "image", "text": "Susan Kalled, PhD", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:26.169+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e467ca10-1ec4-41d7-a10e-5a1994e6aba0", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.3, "x": 0.65, "y": 0.25 }, "kind": "list", "text": "Board of Directors list including Carl L. Gordon, Ellen Chiniara, Phil Ferneau, Mary Ann Gray, Thomas Schuetz, Stephen Squinto, Miranda Toledano", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:26.169+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1a319a5f-f5a9-4e29-957e-addb03779aa3", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.4, "x": 0.02, "y": 0.06 }, "kind": "title", "text": "Seasoned Leadership Team", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:26.169+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8be43417-6f70-4319-b22a-a4942b998264", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 4, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 4, "name": "Team", "beatId": "71a3ea24-1623-4157-b008-1b14b37e7bbc", "matchId": "f3296a8e-e181-40c4-ac34-35cba57d4f6c", "beatType": { "name": "Team", "slug": "sequoia-pitch-team", "status": "active", "canonId": "019dd9b8-23c9-746f-aaf9-2f5d83892cf3", "version": 1, "description": null }, "evidence": "The team bio section presents the company's leadership team", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 23, "from": 3, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "623768d0-5f70-4f8f-9e81-1e86d7a34667", "evidence": "The deck presents a sense of urgency and potential benefits of investing in the company", "position": 0, "objective": "Highlight the potential consequences of not investing in Compass Therapeutics", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:21:57.918341+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 5, "type": "resolution", "title": "The slide uses a Gantt-style layout to track clinical phases and regulatory milestones.", "function": "plan_implementation", "rawType": "timeline", "block": null, "metadata": { "slideType": "timeline", "slideTypeCanon": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-0851-75eb-b758-ea2965e7739a", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "sparse", "densityScore": 7, "componentCount": 2, "textChars": 82, "nDataPoints": 0, "notes": "The slide uses a Gantt-style layout to track clinical phases and regulatory milestones.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:52:20.516+00", "seconds": 2.946, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de072-afcf-751b-be79-65bbe03fb0c7/5", "deck": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7", "deckAnchor": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7#slide-5", "deckJson": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.9, "x": 0.05, "y": 0.2 }, "kind": "framework", "text": "Gantt-style clinical development timeline", "attrs": null, "canon": { "kind": { "name": "Framework", "slug": "framework", "status": "active", "canonId": "019de52c-fa18-77c6-b10a-ccb8277ac0fa", "version": 1, "description": "Named conceptual framework instance." }, "tool": null, "subkind": { "name": "Framework instance", "slug": "instance", "status": "active", "canonId": "019de52d-05a2-72af-be0b-7edc60708a03", "version": 1, "description": null }, "framework": null }, "subkind": "instance", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.516+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d9d6b084-d1c2-48e5-8fd0-0d1fbbc2f935", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.7, "x": 0.15, "y": 0.1 }, "kind": "title", "text": "Key Events Expected in the Next 24 Months", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.516+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c3c1bf5e-2c06-4add-b6f2-62cfd63a3685", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Gantt chart", "slug": "gantt-chart", "status": "active", "bestFor": null, "canonId": "019de52d-1fa2-7206-bb14-bb9ff5fccdba", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "17f8af27-8194-424b-ae14-78fe296eaf53", "evidence": "framework/instance: Gantt-style clinical development timeline", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:00:31.441164+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "0edec7f2-091f-4fba-b4fd-97bb38d9e417", "evidence": "Visual representation of project schedules and milestones over time.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:52:20.516+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "frameworkName": "gantt-chart" } ], "arcBeats": [], "loops": [ { "to": 23, "from": 3, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "623768d0-5f70-4f8f-9e81-1e86d7a34667", "evidence": "The deck presents a sense of urgency and potential benefits of investing in the company", "position": 0, "objective": "Highlight the potential consequences of not investing in Compass Therapeutics", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:21:57.918341+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 6, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 14, "componentCount": 3, "textChars": 104, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 15:31:54.154+00", "seconds": 2.012, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de072-afcf-751b-be79-65bbe03fb0c7/6", "deck": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7", "deckAnchor": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7#slide-6", "deckJson": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7.json" }, "components": [ { "bbox": { "h": 0.02, "w": 0.24, "x": 0.38, "y": 0.94 }, "kind": "disclaimer", "text": "DO NOT DISTRIBUTE WITHOUT PERMISSION | © 2022", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 15:31:54.154+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1bd31ec6-95dd-4fa2-9d1a-67ad0986ee1a", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.54, "x": 0.07, "y": 0.47 }, "kind": "paragraph", "text": "CTX-009 – DLL4 X VEGF-A bispecific antibody", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 15:31:54.154+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "644fdbe1-3f84-41e7-9db6-316e438d24ef", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.38, "x": 0.07, "y": 0.28 }, "kind": "title", "text": "Targeted Therapy", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 15:31:54.154+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7574a3c9-6278-4e91-869f-459060b1a185", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Section divider", "slug": "section-divider", "status": "active", "bestFor": null, "canonId": "019dd9e1-4c66-707d-8d1f-6e14547134c7", "version": 1, "bodyDocId": null, "description": "A transitional slide marking the start of a new section.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "88341ce8-75e7-45b3-a009-9768d3e6da38", "evidence": "paragraph/paragraph: CTX-009 – DLL4 X VEGF-A bispecific antibody", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:00:31.56609+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 23, "from": 3, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "623768d0-5f70-4f8f-9e81-1e86d7a34667", "evidence": "The deck presents a sense of urgency and potential benefits of investing in the company", "position": 0, "objective": "Highlight the potential consequences of not investing in Compass Therapeutics", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:21:57.918341+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 7, "type": "setup", "function": "inspire_vision", "rawType": "vision", "block": null, "metadata": { "slideType": "vision", "slideTypeCanon": { "name": "Vision", "slug": "vision", "status": "active", "canonId": "019de52d-0f7e-7689-8010-992b1a43b6b9", "version": 1, "description": null }, "function": "inspire_vision", "functionCanon": { "name": "Inspire vision", "slug": "inspire_vision", "status": "active", "canonId": "019de52d-16d0-7756-83de-376eeac6fa40", "version": 1, "description": null }, "density": "dense", "densityScore": 50, "componentCount": 5, "textChars": 460, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:52:20.934+00", "seconds": 3.169, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de072-afcf-751b-be79-65bbe03fb0c7/7", "deck": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7", "deckAnchor": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7#slide-7", "deckJson": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7.json" }, "components": [ { "bbox": { "h": 0.028, "w": 0.238, "x": 0.381, "y": 0.944 }, "kind": "disclaimer", "text": "DO NOT DISTRIBUTE WITHOUT PERMISSION | © 2022", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.934+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "88ad5c0b-4381-4d92-88b4-40a001e6b0ce", "parentComponentId": null }, { "bbox": { "h": 0.333, "w": 0.944, "x": 0.028, "y": 0.392 }, "kind": "list", "text": "Oncology: Demonstrated activity in 3rd/4th line settings (Cholangiocarcinoma, Colorectal, Gastric, Pancreatic); Ovarian potential; Front line therapy potential; Other indications", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.934+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "81adb78d-72ae-4144-9073-4fc470695f9c", "parentComponentId": null }, { "bbox": { "h": 0.125, "w": 0.944, "x": 0.028, "y": 0.692 }, "kind": "list", "text": "Ophthalmology: Potential to address AMD and DME based on mechanism; Consideration for partnership", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.934+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a84ebd59-e180-4b6e-bd22-8928ac56e909", "parentComponentId": null }, { "bbox": { "h": 0.125, "w": 0.944, "x": 0.028, "y": 0.242 }, "kind": "list", "text": "Best-in-class DLL4 x VEGF-A bispecific; Phase 2/3 ready, with parallel active development in S. Korea and China", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.934+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f921da00-0cf1-46b2-989e-0244b7f5b797", "parentComponentId": null }, { "bbox": { "h": 0.083, "w": 0.524, "x": 0.028, "y": 0.138 }, "kind": "title", "text": "CTX-009: Vision and Potential", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.934+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e919a81b-2f4b-4529-9529-3e1e8564f9cb", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 7, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Solution", "beatId": "88e44242-ad4a-482c-b72f-501a68ee73eb", "matchId": "f3296a8e-e181-40c4-ac34-35cba57d4f6c", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The vision and potential section presents CTX-009 as a potential solution", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 23, "from": 3, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "623768d0-5f70-4f8f-9e81-1e86d7a34667", "evidence": "The deck presents a sense of urgency and potential benefits of investing in the company", "position": 0, "objective": "Highlight the potential consequences of not investing in Compass Therapeutics", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:21:57.918341+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 8, "type": "evidence", "title": "The slide presents key clinical trial results for a drug candidate, focusing on response rates.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "balanced", "densityScore": 43, "componentCount": 4, "textChars": 345, "nDataPoints": 4, "notes": "The slide presents key clinical trial results for a drug candidate, focusing on response rates.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:52:20.836+00", "seconds": 2.755, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de072-afcf-751b-be79-65bbe03fb0c7/8", "deck": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7", "deckAnchor": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7#slide-8", "deckJson": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.4, "x": 0.04, "y": 0.9 }, "kind": "disclaimer", "text": "* 3 PRs have been confirmed by RECIST 1.1, 1 PR is unconfirmed", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.836+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1de67c97-af54-4085-8218-8dc23865617d", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.4, "x": 0.55, "y": 0.25 }, "kind": "list", "text": "Clinical Benefit Rate at the Efficacious Dose (10-12.5 mg/kg): Monotherapy: 68.8% (11/16), Combination: 76.5% (13/17)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.836+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d41b0696-f874-43d3-aebc-dc6dc62f8347", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.4, "x": 0.05, "y": 0.25 }, "kind": "list", "text": "Overall Response Rate at the Efficacious Dose (10-12.5 mg/kg): Monotherapy: 18.8% ORR (3/16), Combination: 23.5% ORR (4/17)*", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.836+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f4679c7f-fef4-4e59-b49a-488c1b807cae", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.75, "x": 0.05, "y": 0.13 }, "kind": "title", "text": "CTX-009 - Phase 1 Studies Clinical Summary", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.836+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2d68ca45-e7e6-4026-bc50-9d0dec6812e3", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 12, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 8, "name": "Product", "beatId": "c48aac4e-cbcc-46b6-a057-f734bc543a6f", "matchId": "f3296a8e-e181-40c4-ac34-35cba57d4f6c", "beatType": { "name": "Product", "slug": "sequoia-pitch-product", "status": "active", "canonId": "019dd9b8-2259-77df-a937-8b665c8066fe", "version": 1, "description": null }, "evidence": "The traction section presents clinical data for CTX-009", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 23, "from": 3, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "623768d0-5f70-4f8f-9e81-1e86d7a34667", "evidence": "The deck presents a sense of urgency and potential benefits of investing in the company", "position": 0, "objective": "Highlight the potential consequences of not investing in Compass Therapeutics", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:21:57.918341+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 9, "type": "setup", "title": "Uses the Simon 2-Stage adaptive design framework.", "function": "present_framework", "rawType": "appendix_methodology", "block": null, "metadata": { "slideType": "appendix_methodology", "slideTypeCanon": { "name": "Appendix methodology", "slug": "appendix_methodology", "status": "active", "canonId": "019de52d-07d9-726c-8599-167f2d2ffaa7", "version": 1, "description": null }, "function": "present_framework", "functionCanon": { "name": "Present framework", "slug": "present_framework", "status": "active", "canonId": "019de52d-1403-7667-9100-d2ac6709f750", "version": 1, "description": null }, "density": "dense", "densityScore": 52, "componentCount": 5, "textChars": 359, "nDataPoints": 4, "notes": "Uses the Simon 2-Stage adaptive design framework.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:52:21.638+00", "seconds": 3.412, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de072-afcf-751b-be79-65bbe03fb0c7/9", "deck": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7", "deckAnchor": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7#slide-9", "deckJson": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7.json" }, "components": [ { "bbox": null, "kind": "framework", "text": "Simon 2 Stage adaptive design", "attrs": null, "canon": { "kind": { "name": "Framework", "slug": "framework", "status": "active", "canonId": "019de52c-fa18-77c6-b10a-ccb8277ac0fa", "version": 1, "description": "Named conceptual framework instance." }, "tool": null, "subkind": { "name": "Framework instance", "slug": "instance", "status": "active", "canonId": "019de52d-05a2-72af-be0b-7edc60708a03", "version": 1, "description": null }, "framework": null }, "subkind": "instance", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:21.638+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "596b1366-b30f-47ef-9dbb-6eeaafcef863", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.85, "x": 0.03, "y": 0.3 }, "kind": "list", "text": "Patients with biliary tract cancers after one or two prior therapies\nCTX-009 at 10 mg/kg biweekly plus paclitaxel 80 mg/m² weekly 3 of 4 weeks\nSimon 2 Stage adaptive design:", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:21.638+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "06cddfb9-8071-4c50-8d54-034a8f4d721b", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.6, "x": 0.06, "y": 0.61 }, "kind": "list", "text": "Stage 1: 21 patients → ORR\nStage 2: if 3 or more PRs → Stage 2: 45 additional patients", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:21.638+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "78b8056b-bf6d-4972-b19c-fb89bd4b264b", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.25, "x": 0.03, "y": 0.23 }, "kind": "paragraph", "text": "Phase 2 Study Design:", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:21.638+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7ae4ffd9-0af2-4dcf-8578-601c70096b01", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.89, "x": 0.03, "y": 0.13 }, "kind": "title", "text": "Phase 2 Combination Study: CTX-009 Plus Paclitaxel", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:21.638+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "11eccbc8-0936-4e9c-86c2-2540125c0705", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "e8d09af9-daaa-4808-bf99-2e27a066871a", "evidence": "Explicit mention of 'Simon 2 Stage adaptive design' and stage-gate criteria.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:52:21.638+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "frameworkName": "Simon 2-Stage Design" } ], "arcBeats": [ { "to": 12, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 8, "name": "Product", "beatId": "c48aac4e-cbcc-46b6-a057-f734bc543a6f", "matchId": "f3296a8e-e181-40c4-ac34-35cba57d4f6c", "beatType": { "name": "Product", "slug": "sequoia-pitch-product", "status": "active", "canonId": "019dd9b8-2259-77df-a937-8b665c8066fe", "version": 1, "description": null }, "evidence": "The traction section presents clinical data for CTX-009", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 23, "from": 3, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "623768d0-5f70-4f8f-9e81-1e86d7a34667", "evidence": "The deck presents a sense of urgency and potential benefits of investing in the company", "position": 0, "objective": "Highlight the potential consequences of not investing in Compass Therapeutics", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:21:57.918341+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 10, "type": "analysis", "title": "The slide highlights a specific row (2 prior systemic therapies) with a red box.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "balanced", "densityScore": 39, "componentCount": 4, "textChars": 254, "nDataPoints": 14, "notes": "The slide highlights a specific row (2 prior systemic therapies) with a red box.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:52:20.848+00", "seconds": 2.613, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de072-afcf-751b-be79-65bbe03fb0c7/10", "deck": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7", "deckAnchor": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7#slide-10", "deckJson": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7.json" }, "components": [ { "bbox": { "h": 0.06, "w": 0.46, "x": 0.502, "y": 0.412 }, "kind": "legend", "text": "Red box highlighting 2 prior systemic therapies", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.848+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "26e9c898-fb4d-4f30-8e81-4a2438cebfb7", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.46, "x": 0.028, "y": 0.25 }, "kind": "table", "text": "Left table showing Age, Gender, and ECOG status for 24 patients.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.848+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3211ebd5-9e18-4408-824a-ee5306d80a85", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.46, "x": 0.502, "y": 0.25 }, "kind": "table", "text": "Right table showing Prior systemic therapies, Prior Gem/Cis regimen, and BTC subtype for 24 patients.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.848+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5f2def5d-4a36-43fe-aef1-3e8cd6cb41dd", "parentComponentId": null }, { "bbox": { "h": 0.083, "w": 0.773, "x": 0.028, "y": 0.115 }, "kind": "title", "text": "Phase 2: Patient Baseline and Demographics", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.848+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0608ca48-45dd-4bed-ac88-7ccd298afc8b", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "6dfa0ce8-7f12-4627-a26b-f26340958b08", "evidence": "table/data: Right table showing Prior systemic therapies, Prior Gem/Cis regimen, and BTC subtype for 24 patients.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:00:30.744076+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 12, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 8, "name": "Product", "beatId": "c48aac4e-cbcc-46b6-a057-f734bc543a6f", "matchId": "f3296a8e-e181-40c4-ac34-35cba57d4f6c", "beatType": { "name": "Product", "slug": "sequoia-pitch-product", "status": "active", "canonId": "019dd9b8-2259-77df-a937-8b665c8066fe", "version": 1, "description": null }, "evidence": "The traction section presents clinical data for CTX-009", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 23, "from": 3, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "623768d0-5f70-4f8f-9e81-1e86d7a34667", "evidence": "The deck presents a sense of urgency and potential benefits of investing in the company", "position": 0, "objective": "Highlight the potential consequences of not investing in Compass Therapeutics", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:21:57.918341+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 11, "type": "evidence", "title": "The chart uses a standard oncology waterfall plot format to visualize tumor shrinkage.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 54, "componentCount": 5, "textChars": 350, "nDataPoints": 22, "notes": "The chart uses a standard oncology waterfall plot format to visualize tumor shrinkage.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:52:21.628+00", "seconds": 3.159, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de072-afcf-751b-be79-65bbe03fb0c7/11", "deck": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7", "deckAnchor": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7#slide-11", "deckJson": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.4, "x": 0.54, "y": 0.84 }, "kind": "callout", "text": "Partial Responses: 9 confirmed, 1 pending confirmation", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:21.628+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c94f528f-586d-4abf-943b-6a19b623eda1", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.95, "x": 0.03, "y": 0.225 }, "kind": "chart", "text": "Waterfall plot of percent tumor decline by patient", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Waterfall chart", "slug": "waterfall", "status": "active", "canonId": "019de52d-002e-733e-b5cf-dd3beb6692cc", "version": 1, "description": null }, "framework": null }, "subkind": "waterfall", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:21.628+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cdaaed77-6aa2-44ab-b081-afe597d6bd57", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.25, "x": 0.06, "y": 0.62 }, "kind": "legend", "text": "Intrahepatic cholangiocarcinoma, Extrahepatic cholangiocarcinoma, Gallbladder cancer, Ampullary cancer", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:21.628+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5034b78b-2a0d-42f7-b823-48cdee675f62", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.06, "y": 0.89 }, "kind": "paragraph", "text": "2 patients were not evaluable (one missing post baseline scan; one had a scan outside of protocol window)", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:21.628+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7575fdfd-2114-4d82-b048-5bf2292aa937", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.75, "x": 0.03, "y": 0.13 }, "kind": "title", "text": "Phase 2 Waterfall: ORR = 42%; CBR = 92%", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:21.628+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9a7cc925-61a0-4894-911c-b9c439de34d6", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "38ea3ed8-8974-4deb-bd52-0d37bd7060ae", "evidence": "chart/waterfall: Waterfall plot of percent tumor decline by patient", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:00:30.897269+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "db6757e7-b212-42e4-b115-4464aafee089", "evidence": "Standard clinical trial efficacy visualization", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:52:21.628+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "frameworkName": "waterfall-chart" } ], "arcBeats": [ { "to": 12, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 8, "name": "Product", "beatId": "c48aac4e-cbcc-46b6-a057-f734bc543a6f", "matchId": "f3296a8e-e181-40c4-ac34-35cba57d4f6c", "beatType": { "name": "Product", "slug": "sequoia-pitch-product", "status": "active", "canonId": "019dd9b8-2259-77df-a937-8b665c8066fe", "version": 1, "description": null }, "evidence": "The traction section presents clinical data for CTX-009", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 23, "from": 3, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "623768d0-5f70-4f8f-9e81-1e86d7a34667", "evidence": "The deck presents a sense of urgency and potential benefits of investing in the company", "position": 0, "objective": "Highlight the potential consequences of not investing in Compass Therapeutics", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:21:57.918341+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 12, "type": "analysis", "title": "Standard clinical trial swimmer plot showing treatment duration, response (PR/SD), progression (PD), death, and ongoing status.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "balanced", "densityScore": 28, "componentCount": 3, "textChars": 184, "nDataPoints": 25, "notes": "Standard clinical trial swimmer plot showing treatment duration, response (PR/SD), progression (PD), death, and ongoing status.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:52:25.88+00", "seconds": 7.326, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de072-afcf-751b-be79-65bbe03fb0c7/12", "deck": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7", "deckAnchor": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7#slide-12", "deckJson": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.8, "x": 0.07, "y": 0.25 }, "kind": "chart", "text": "Swimmer plot showing patient treatment duration", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:25.88+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2f521520-ab96-43a4-9886-0bf7402e7317", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.25, "x": 0.68, "y": 0.745 }, "kind": "legend", "text": "PR (yellow triangle), SD (orange square), PD (black diamond), Death (star), On-going (arrow)", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:25.88+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a546cddc-064f-46d6-bbc0-985695e5fb75", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.8, "x": 0.03, "y": 0.13 }, "kind": "title", "text": "Swimmer Plot: Median Time on Study ~ 6 Months", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:25.88+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "04f0eb5c-157a-4bbc-9e64-0e1bdbcafeda", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Sparklines (Chart)", "slug": "sparklines-chart", "status": "active", "bestFor": null, "canonId": "019dd956-b3db-7239-aa95-d24b7cdc29e4", "version": 1, "bodyDocId": null, "description": "Word-sized graphics embedded in text for data density", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "6d9ff104-83e3-4ea2-be94-96f4a94efa2a", "evidence": "chart/bar-horizontal: Swimmer plot showing patient treatment duration", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:00:31.040103+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "d90efd02-f67d-438d-9a6c-9204e517492d", "evidence": "Standard clinical trial visualization for patient-level longitudinal data", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:52:25.88+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "frameworkName": "swimmer-plot" } ], "arcBeats": [ { "to": 12, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 8, "name": "Product", "beatId": "c48aac4e-cbcc-46b6-a057-f734bc543a6f", "matchId": "f3296a8e-e181-40c4-ac34-35cba57d4f6c", "beatType": { "name": "Product", "slug": "sequoia-pitch-product", "status": "active", "canonId": "019dd9b8-2259-77df-a937-8b665c8066fe", "version": 1, "description": null }, "evidence": "The traction section presents clinical data for CTX-009", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 23, "from": 3, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "623768d0-5f70-4f8f-9e81-1e86d7a34667", "evidence": "The deck presents a sense of urgency and potential benefits of investing in the company", "position": 0, "objective": "Highlight the potential consequences of not investing in Compass Therapeutics", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:21:57.918341+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 13, "type": "analysis", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "balanced", "densityScore": 25, "componentCount": 3, "textChars": 151, "nDataPoints": 12, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:52:20.681+00", "seconds": 2.107, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de072-afcf-751b-be79-65bbe03fb0c7/13", "deck": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7", "deckAnchor": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7#slide-13", "deckJson": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7.json" }, "components": [ { "bbox": { "h": 0.5, "w": 0.45, "x": 0.03, "y": 0.385 }, "kind": "table", "text": "Phase 2 BTC study of CTX-009 plus paclitaxel table", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.681+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "643b8546-9e34-4968-a855-b454d808206c", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.45, "x": 0.51, "y": 0.385 }, "kind": "table", "text": "Avastin and paclitaxel label information table", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.681+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d67e7f14-1047-45e2-aedd-a5a7394098aa", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.94, "x": 0.03, "y": 0.12 }, "kind": "title", "text": "Safety Data: Treatment-Related ≥ Grade 3 Adverse Events", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.681+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "febd4045-c564-4fd8-a4d9-96994a3f7450", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "f4d3868b-a445-48ed-8cf7-bc0b9730f2be", "evidence": "table/data: Phase 2 BTC study of CTX-009 plus paclitaxel table", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:00:31.147355+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 23, "from": 3, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "623768d0-5f70-4f8f-9e81-1e86d7a34667", "evidence": "The deck presents a sense of urgency and potential benefits of investing in the company", "position": 0, "objective": "Highlight the potential consequences of not investing in Compass Therapeutics", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:21:57.918341+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 14, "type": "resolution", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 32, "componentCount": 3, "textChars": 431, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:52:20.798+00", "seconds": 2.118, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de072-afcf-751b-be79-65bbe03fb0c7/14", "deck": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7", "deckAnchor": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7#slide-14", "deckJson": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7.json" }, "components": [ { "bbox": { "h": 0.02, "w": 0.226, "x": 0.387, "y": 0.945 }, "kind": "disclaimer", "text": "DO NOT DISTRIBUTE WITHOUT PERMISSION | 2022", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.798+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4833622f-e036-4069-abe2-97e29785522b", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.944, "x": 0.028, "y": 0.275 }, "kind": "list", "text": "Initiate Stage 2 of the Phase 2 BTC study in the US in early Q3\nInitiate Phase 2/3 study in patients with colorectal cancer in the third line setting in the US in Q4 2022\nInitiate Phase 2 study in patients with advanced ovarian cancer in the US in Q1 2023\nContinue to evaluate additional indications for CTX-009 both as a monotherapy and in combination with chemotherapy", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.798+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "359ab1dd-2bfa-4eaf-bac0-072b7d0aef5c", "parentComponentId": null }, { "bbox": { "h": 0.075, "w": 0.357, "x": 0.028, "y": 0.145 }, "kind": "title", "text": "CTX-009 Next Steps", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.798+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e3648b6b-d59d-4e07-b267-1cd1f69183ab", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 23, "from": 3, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "623768d0-5f70-4f8f-9e81-1e86d7a34667", "evidence": "The deck presents a sense of urgency and potential benefits of investing in the company", "position": 0, "objective": "Highlight the potential consequences of not investing in Compass Therapeutics", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:21:57.918341+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 15, "type": "evidence", "title": "Includes comparative data against FOLFOX and TOPAZ-1.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "balanced", "densityScore": 39, "componentCount": 2, "textChars": 536, "nDataPoints": 6, "notes": "Includes comparative data against FOLFOX and TOPAZ-1.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:52:21.737+00", "seconds": 2.85, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de072-afcf-751b-be79-65bbe03fb0c7/15", "deck": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7", "deckAnchor": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7#slide-15", "deckJson": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.95, "x": 0.02, "y": 0.25 }, "kind": "list", "text": "24 patients with BTC have been enrolled and dosed\n10 partial responses (PRs) for a 42% ORR in patients treated in the second- and third-line settings (54% of patient were treated in the 3rd line setting)\nOther regimens in BTC:\nFOLFOX (NCCN guidelines): 5% ORR in the second-line setting\nTOPAZ-1 (Phase 3 development): 26.7% ORR for Gem/Cis/Durvalumab (anti-PD-L1) in the first-line setting\nMedian time on study approximately 6 months, with 7 patients ongoing\nAdverse event profile similar to Phase 1", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:21.737+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0740b872-6278-41ee-afe5-99b5973903b5", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.6, "x": 0.02, "y": 0.14 }, "kind": "title", "text": "CTX-009 Interim Phase 2 Study Summary", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:21.737+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ce3d0c70-ede7-4672-b085-fc772710a3dc", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "4eeff147-fa1c-4fa6-a837-389572a81191", "evidence": "list/bullet: 24 patients with BTC have been enrolled and dosed", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:00:31.320725+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 15, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 23, "from": 3, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "623768d0-5f70-4f8f-9e81-1e86d7a34667", "evidence": "The deck presents a sense of urgency and potential benefits of investing in the company", "position": 0, "objective": "Highlight the potential consequences of not investing in Compass Therapeutics", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:21:57.918341+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 16, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 14, "componentCount": 3, "textChars": 106, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:52:20.984+00", "seconds": 2.024, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de072-afcf-751b-be79-65bbe03fb0c7/16", "deck": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7", "deckAnchor": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7#slide-16", "deckJson": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.3, "x": 0.35, "y": 0.95 }, "kind": "disclaimer", "text": "DO NOT DISTRIBUTE WITHOUT PERMISSION | © 2022", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.984+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "35952cf4-44e5-4e44-9e95-a77221fb4736", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.5, "x": 0.05, "y": 0.45 }, "kind": "paragraph", "text": "CTX-471 – CD137 monoclonal antibody", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.984+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d76d727b-60e0-4894-a77d-4b425689dd4a", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.5, "x": 0.05, "y": 0.3 }, "kind": "title", "text": "T Cell and NK Cell Agonist", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:20.984+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "49a0c868-6bd0-4230-b103-ec91289bf346", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 23, "from": 3, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "623768d0-5f70-4f8f-9e81-1e86d7a34667", "evidence": "The deck presents a sense of urgency and potential benefits of investing in the company", "position": 0, "objective": "Highlight the potential consequences of not investing in Compass Therapeutics", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:21:57.918341+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 17, "type": "resolution", "title": "Includes a molecular visualization of the antibody-receptor interaction.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 66, "componentCount": 6, "textChars": 756, "nDataPoints": 0, "notes": "Includes a molecular visualization of the antibody-receptor interaction.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:52:25.909+00", "seconds": 6.846, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de072-afcf-751b-be79-65bbe03fb0c7/17", "deck": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7", "deckAnchor": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7#slide-17", "deckJson": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.3, "x": 0.65, "y": 0.25 }, "kind": "image", "text": "Molecular structure diagram", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:25.909+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3fa05d89-fe3b-43a0-b5cb-b5b3c47860fd", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.6, "x": 0.03, "y": 0.42 }, "kind": "list", "text": "Phase 1 Study Update\nMonotherapy in the post checkpoint inhibitor patients\nMonotherapy Phase 1a multiple ascending dose study completed\nNear PR in a patient with mucosal melanoma\nProlonged stable disease in two patients with NSCLC\nMTD defined by immune thrombocytopenia\nMonotherapy Phase 1b dose expansion study nearing completion\n3 PRs observed so far: small cell lung cancer, mucosal melanoma and metastatic melanoma", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:25.909+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "37e14676-8a8b-4189-b838-2577afd5d716", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.6, "x": 0.03, "y": 0.24 }, "kind": "list", "text": "CTX-471: next generation CD137 agonist\nFully human, IgG4, optimized affinity for agonistic antibody\nUnique epitope: non-ligand blocking", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:25.909+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ed0ec5c6-7130-47d2-b61c-9a8c73628ea9", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.6, "x": 0.03, "y": 0.17 }, "kind": "paragraph", "text": "NOVEL EPITOPE WITH DIFFERENTIATED ACTIVITY OBSERVED IN EXTENSIVE PRECLINICAL DATA*", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:25.909+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2aa262c9-88b8-4b0b-84a7-62d5d8c3c4b1", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.3, "x": 0.64, "y": 0.88 }, "kind": "source-note", "text": "*Eskiocak, et al. JCI Insight. 2020;5(5):e133647", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:25.909+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2453d462-aa3f-4afb-95f4-a7ae0c99823c", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.7, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "CTX-471: Potential Best-in-Class CD137 Agonist", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:25.909+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fc1e8d73-49c4-4463-9196-2434a6fb0e85", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "daeddc9d-50de-42be-ae24-a25cfb82c367", "evidence": "list/bullet: Phase 1 Study Update", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:00:31.439705+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 17, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 23, "from": 3, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "623768d0-5f70-4f8f-9e81-1e86d7a34667", "evidence": "The deck presents a sense of urgency and potential benefits of investing in the company", "position": 0, "objective": "Highlight the potential consequences of not investing in Compass Therapeutics", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:21:57.918341+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 18, "type": "evidence", "title": "The slide uses medical imaging (CT scans) to demonstrate treatment efficacy.", "function": "illustrate_case", "rawType": "testimonial", "block": null, "metadata": { "slideType": "testimonial", "slideTypeCanon": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52d-0a2d-7782-8a48-7e84df92cc97", "version": 1, "description": null }, "function": "illustrate_case", "functionCanon": { "name": "Illustrate case", "slug": "illustrate_case", "status": "active", "canonId": "019de52d-13b4-772c-bb73-1873612a7463", "version": 1, "description": null }, "density": "dense", "densityScore": 53, "componentCount": 5, "textChars": 397, "nDataPoints": 3, "notes": "The slide uses medical imaging (CT scans) to demonstrate treatment efficacy.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:52:25.265+00", "seconds": 6.17, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de072-afcf-751b-be79-65bbe03fb0c7/18", "deck": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7", "deckAnchor": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7#slide-18", "deckJson": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7.json" }, "components": [ { "bbox": { "h": 0.55, "w": 0.32, "x": 0.02, "y": 0.38 }, "kind": "image", "text": "Baseline CT scan", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Screenshot", "slug": "screenshot", "status": "active", "canonId": "019de52c-fd87-7509-8391-3d79fb339379", "version": 1, "description": null }, "framework": null }, "subkind": "screenshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:25.265+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1505bffe-cbbc-4918-b3e1-c7717852995a", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.32, "x": 0.66, "y": 0.38 }, "kind": "image", "text": "Month 8 CT scan", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Screenshot", "slug": "screenshot", "status": "active", "canonId": "019de52c-fd87-7509-8391-3d79fb339379", "version": 1, "description": null }, "framework": null }, "subkind": "screenshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:25.265+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "50d05330-3d7c-4fc5-94b7-a23b9256e75e", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.32, "x": 0.34, "y": 0.38 }, "kind": "image", "text": "Month 4 CT scan", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Screenshot", "slug": "screenshot", "status": "active", "canonId": "019de52c-fd87-7509-8391-3d79fb339379", "version": 1, "description": null }, "framework": null }, "subkind": "screenshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:25.265+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cbc3be6a-48d8-4fb1-af5f-18b6ef39b893", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.85, "x": 0.08, "y": 0.22 }, "kind": "list", "text": "66 y.o. man with advanced SCLC: Carboplatin/etoposide plus atezolizumab first line; nivolumab second line\nMultiple metastases: Largest mass (RUL Lung) shown below, ~ 4 cm at baseline -> 40% total decline\nConfirmed and durable PR at Month 13", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:25.265+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0a74821d-8a6c-48cc-8270-24bae769cae0", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.96, "x": 0.02, "y": 0.05 }, "kind": "title", "text": "Partial Response in a Patient with Small Cell Lung Cancer after Progression on Atezolizumab/Chemo and Nivolumab", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:25.265+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d959f6de-374d-4ae9-a233-0ed50f2c2e76", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 23, "from": 3, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "623768d0-5f70-4f8f-9e81-1e86d7a34667", "evidence": "The deck presents a sense of urgency and potential benefits of investing in the company", "position": 0, "objective": "Highlight the potential consequences of not investing in Compass Therapeutics", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:21:57.918341+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 19, "type": "resolution", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "dense", "densityScore": 65, "componentCount": 6, "textChars": 719, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:52:21.95+00", "seconds": 2.787, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de072-afcf-751b-be79-65bbe03fb0c7/19", "deck": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7", "deckAnchor": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7#slide-19", "deckJson": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7.json" }, "components": [ { "bbox": { "h": 0.02, "w": 0.235, "x": 0.382, "y": 0.945 }, "kind": "disclaimer", "text": "DO NOT DISTRIBUTE WITHOUT PERMISSION | © 2022", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:21.95+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "737ac85e-e8cd-4ad3-aa7c-5a9c6ed9e082", "parentComponentId": null }, { "bbox": { "h": 0.165, "w": 0.945, "x": 0.028, "y": 0.235 }, "kind": "list", "text": "Phase 1b study nearing completion; Well tolerated; Three partial responses as a monotherapy agent in the post PD-1/PD-L1 patient population; Small cell lung cancer and melanoma (two patients)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:21.95+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "34548ad5-8405-4fc9-bac9-f37a115fac69", "parentComponentId": null }, { "bbox": { "h": 0.105, "w": 0.935, "x": 0.028, "y": 0.715 }, "kind": "list", "text": "First line Small Cell Lung Cancer; Carboplatin/etoposide/atezolizumab induction -> atezolizumab plus CTX-471 maintenance; Straightforward randomized approval strategy: Atezo +/- CTX-471", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:21.95+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "519c5895-c375-4cbf-8616-d955cd9599fa", "parentComponentId": null }, { "bbox": { "h": 0.105, "w": 0.515, "x": 0.028, "y": 0.555 }, "kind": "list", "text": "Post PD-1/PD-L1 Salvage Study; Progression on a labeled PD-1/PD-L1 regimen; Followed by PD-1 salvage plus CTX-471", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:21.95+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "547b341e-7cce-4b1d-9b53-729cff61d01b", "parentComponentId": null }, { "bbox": { "h": 0.105, "w": 0.945, "x": 0.028, "y": 0.435 }, "kind": "list", "text": "Initiate a Phase 1b combination study with a PD-1 inhibitor; Abbreviated CTX-471 dose escalation into the PD-1 regimen, followed by a cohort expansion", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:21.95+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e1ee8129-eb24-45ae-8ac9-c28cfd0ba390", "parentComponentId": null }, { "bbox": { "h": 0.055, "w": 0.582, "x": 0.028, "y": 0.155 }, "kind": "title", "text": "CTX-471: Clinical Development Plans", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:21.95+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b35961fd-2106-4d59-a1d9-e45441960eba", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 23, "from": 3, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "623768d0-5f70-4f8f-9e81-1e86d7a34667", "evidence": "The deck presents a sense of urgency and potential benefits of investing in the company", "position": 0, "objective": "Highlight the potential consequences of not investing in Compass Therapeutics", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:21:57.918341+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 20, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 14, "componentCount": 3, "textChars": 117, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:52:22.368+00", "seconds": 3.083, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de072-afcf-751b-be79-65bbe03fb0c7/20", "deck": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7", "deckAnchor": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7#slide-20", "deckJson": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7.json" }, "components": [ { "bbox": { "h": 0.02, "w": 0.3, "x": 0.35, "y": 0.95 }, "kind": "disclaimer", "text": "DO NOT DISTRIBUTE WITHOUT PERMISSION | © 2022", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:22.368+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c45bb99c-2d77-4162-a25f-5aea2a463e81", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.6, "x": 0.05, "y": 0.45 }, "kind": "paragraph", "text": "CTX-8371 – PD-1 x PD-L1 bispecific antibody", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:22.368+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4100f7b6-00bd-48ff-a0e0-118ac0acf55c", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.6, "x": 0.05, "y": 0.3 }, "kind": "title", "text": "Bispecific Checkpoint Blocker", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:22.368+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0a3f47e6-d4ac-4c13-95d1-a2d00cc78927", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 23, "from": 3, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "623768d0-5f70-4f8f-9e81-1e86d7a34667", "evidence": "The deck presents a sense of urgency and potential benefits of investing in the company", "position": 0, "objective": "Highlight the potential consequences of not investing in Compass Therapeutics", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:21:57.918341+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 21, "type": "resolution", "title": "The slide uses a process flow to show the transition from testing a hypothesis to the identification of the lead candidate CTX-8371, supported by two experiment", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 49, "componentCount": 5, "textChars": 334, "nDataPoints": 2, "notes": "The slide uses a process flow to show the transition from testing a hypothesis to the identification of the lead candidate CTX-8371, supported by two experimental charts.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:52:22.194+00", "seconds": 2.74, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de072-afcf-751b-be79-65bbe03fb0c7/21", "deck": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7", "deckAnchor": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7#slide-21", "deckJson": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.35, "x": 0.05, "y": 0.23 }, "kind": "chart", "text": "Unexpected synergistic activity of PD-1/PD-L1 combination in bispecific Stitchmab format", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Grouped bar chart", "slug": "bar-grouped", "status": "active", "canonId": "019de52c-ff3b-751e-a8ff-f21ff11097b1", "version": 1, "description": null }, "framework": null }, "subkind": "bar-grouped", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:22.194+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8a977814-6939-433a-b96c-b242be877217", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.3, "x": 0.65, "y": 0.4 }, "kind": "chart", "text": "Our PD-1xPD-L1 bispecifics observed to outperform PD-1 blockers in T-cell activation assay", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:22.194+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "923546e5-3431-41f1-b10b-792b5fc114b6", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.15, "x": 0.45, "y": 0.4 }, "kind": "image", "text": "CTX-8371 structure diagram", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:22.194+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "752c34c5-9765-4ffc-9923-11aeb5204b47", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.25, "x": 0.36, "y": 0.31 }, "kind": "paragraph", "text": "Common Light Chain bispecifics were generated to test therapeutic hypothesis", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:22.194+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6fc5a66f-bcd0-4e06-b1f8-00d32a50019c", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.8, "x": 0.05, "y": 0.12 }, "kind": "title", "text": "StitchMab™ Platform was Utilized to Identify CTX-8371:", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:22.194+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "79d7b79f-9d36-4cf1-9f1f-d00761ac14a5", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 23, "from": 3, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "623768d0-5f70-4f8f-9e81-1e86d7a34667", "evidence": "The deck presents a sense of urgency and potential benefits of investing in the company", "position": 0, "objective": "Highlight the potential consequences of not investing in Compass Therapeutics", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:21:57.918341+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 22, "type": "resolution", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 37, "componentCount": 2, "textChars": 489, "nDataPoints": 5, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:52:25.669+00", "seconds": 6.199, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de072-afcf-751b-be79-65bbe03fb0c7/22", "deck": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7", "deckAnchor": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7#slide-22", "deckJson": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.88, "x": 0.028, "y": 0.25 }, "kind": "list", "text": "IND enabling studies underway; Primate dose range finding study completed; Manufacturing initiated; Pre-IND meeting completed; Phase 1 study planning; Multiple ascending dose dose-escalation study; 5 doses planned: 0.1, 0.3, 1.0, 3.0, and 10 mg/kg; Post PD-1 or PD-L1 patient population; PD-1 shedding on peripheral T cells as a pharmacodynamic marker; IND submission targeted for Q1 2023; Potential for proprietary combination regimens with CTX-009 and CTX-471", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:25.669+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f5bc0e5b-1838-4c79-b018-20b4e5af5548", "parentComponentId": null }, { "bbox": { "h": 0.065, "w": 0.515, "x": 0.028, "y": 0.145 }, "kind": "title", "text": "CTX-8371: Development Status", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:25.669+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "63ca1d2c-7d5c-4003-be65-dc776fe6b414", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 23, "from": 3, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "623768d0-5f70-4f8f-9e81-1e86d7a34667", "evidence": "The deck presents a sense of urgency and potential benefits of investing in the company", "position": 0, "objective": "Highlight the potential consequences of not investing in Compass Therapeutics", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:21:57.918341+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 23, "type": "resolution", "title": "The slide uses a visual legend (checkmarks for completed, stars for in-progress) to track status of specific drug development milestones.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "dense", "densityScore": 51, "componentCount": 4, "textChars": 486, "nDataPoints": 8, "notes": "The slide uses a visual legend (checkmarks for completed, stars for in-progress) to track status of specific drug development milestones.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:52:22.248+00", "seconds": 2.775, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de072-afcf-751b-be79-65bbe03fb0c7/23", "deck": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7", "deckAnchor": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7#slide-23", "deckJson": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.35, "x": 0.05, "y": 0.45 }, "kind": "image", "text": "Compass Therapeutics Logo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:22.248+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "aecc0d40-a8a2-4e49-8b70-adfba6e083db", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.2, "x": 0.4, "y": 0.87 }, "kind": "legend", "text": "Completed; In progress", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:22.248+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ac928cf1-e299-4f89-ae70-776e101c7f3a", "parentComponentId": null }, { "bbox": { "h": 0.63, "w": 0.63, "x": 0.29, "y": 0.21 }, "kind": "list", "text": "Completed CTX-009 Phase 1b Study (H2 2021); CTX-009 US IND clearance (Q1 2022); Initiate CTX-009 US BTC Phase 2/3 Study (Q2 2022); Complete CTX-471 Phase 1b monotherapy study (Q2 2022); Complete CTX-8371 GMP Manufacturing (H1 2022); Protocol submission for CTX-009 CRC Study (H2 2022); Protocol Submission for CTX-471 plus PD-1 Study (H2 2022); Initiate CTX-471 plus PD-1 Study (H2 2022)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Timeline item", "slug": "timeline-item", "status": "active", "canonId": "019de52c-fd0e-74ce-9443-440fbd8c23b4", "version": 1, "description": null }, "framework": null }, "subkind": "timeline-item", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:22.248+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dfc92183-65fe-4c3f-add0-5a6fa63e73f0", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.67, "x": 0.04, "y": 0.11 }, "kind": "title", "text": "Key Milestones Expected Across Our Portfolio in 2022", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:52:22.248+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2f819f08-5997-4e8d-a6f9-ccfc5375937b", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "c68532ab-48ec-4b8e-9c20-fc6c12f161d3", "evidence": "Visual representation of milestones over time", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:52:22.248+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 23, "frameworkName": "gantt-chart" } ], "arcBeats": [], "loops": [ { "to": 23, "from": 3, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "623768d0-5f70-4f8f-9e81-1e86d7a34667", "evidence": "The deck presents a sense of urgency and potential benefits of investing in the company", "position": 0, "objective": "Highlight the potential consequences of not investing in Compass Therapeutics", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:21:57.918341+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true } ], "arcBeats": [ { "from": 3, "to": 3, "label": "Problem", "description": "The executive summary presents the company's focus on cancer and autoimmune diseases" }, { "from": 7, "to": 7, "label": "Solution", "description": "The vision and potential section presents CTX-009 as a potential solution" }, { "from": 8, "to": 12, "label": "Product", "description": "The traction section presents clinical data for CTX-009" }, { "from": 4, "to": 4, "label": "Team", "description": "The team bio section presents the company's leadership team" } ], "loops": [ { "from": 3, "to": 23, "label": "Cost Of Inaction", "description": "Highlight the potential consequences of not investing in Compass Therapeutics" } ] }